1.
|
Phase: Phase IV
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: U2963n, NCT00097565
|
|
2.
|
Phase: Phase IV
Type: Supportive care, Treatment
Status: Active
Age: 15 to 70
Sponsor: Other
Protocol IDs: OLSG-0401, NCT00162955
|
|
3.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 15
Sponsor: Other
Protocol IDs: GMALL05, NCT00199082
|
|
4.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: Other
Protocol IDs: MCC-14178, NCT00361140
|
|
5.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 60
Sponsor: Other
Protocol IDs: Hemato INCAN 01/2007, NCT00429065
|
|
6.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 2006-003750-23, LINFOTARGAM, NCT00466258
|
|
7.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: Other
Protocol IDs: GMALL04, NCT00199017
|
|
8.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HEMOS ALL1105, NCT00797810
|
|
9.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: TPH/SCU-IMed 01/08, NCT00838019
|
|
10.
|
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 1. NHL, non, NCT00969462
|
|
11.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 4 to 70
Sponsor: Other
Protocol IDs: RPCI-RP-9815, NCI-V99-1527, NCT00003816, RP 98-15
|
|
12.
|
Phase: Phase III, Phase II
Type: Supportive care, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: Levosta-CBF-02/04, NCT00215007
|
|
13.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 12 to 55
Sponsor: Pharmaceutical / Industry
Protocol IDs: GC P#02.01.001, NCT00469729
|
|
14.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 4 and over
Sponsor: NCI
Protocol IDs: RPCI-I-72806, I 72806, NCT00536601
|
|
15.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 19 to 70
Sponsor: Other
Protocol IDs: F080429003, UAB-0775, NCT00714259
|
|
16.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: NILG-ALL 10/07, NCT00795756
|
|
17.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: NHL 7-2008, NCT00877214
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: NCI
Protocol IDs: SWOG-S9704, CAN-NCIC-LY11, CALGB-59903, ECOG-S9704, S9704, NCT00004031, LY11
|
|
19.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: CKTO-2000-06, HOVON-44, HOVON-44/CKVO-2000-06, EU-20042, ISRCTN95614846, NCT00012051
|
|
20.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-20971, EORTC-22997, NCT00014326
|
|
21.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 61 to 80
Sponsor: Other
Protocol IDs: DSHNHL-1999-1A, EU-20243, NCT00052936
|
|
22.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 75
Sponsor: NCI
Protocol IDs: FHCRC-1813.00, 5666, NCT00075478
|
|
23.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: Other
Protocol IDs: CAN-NCIC-LY12, NCT00078949, LY12
|
|
24.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CCBX001-049, NCT00078598
|
|
25.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: CRUK-2004-001621-16, EU-20509, ROCHE-CRUK-001621-16, NCT00112931
|
